Clinical pharmacokinetics and pharmacodynamics of G3139 (Genta Incorporated) antisense oligonucleotide targeting BCL-2.

被引：0
|
作者：
Fingert, HJ [1 ]
Klem, RE [1 ]
机构：
[1] Genta Inc, Lexington, MA USA
来源：
CLINICAL CANCER RESEARCH | 1999年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585
引用
收藏
页码：3847S / 3848S
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice
    Yu, RZ
    Zhang, H
    Geary, RS
    Graham, M
    Masarjian, L
    Lemonidis, K
    Crooke, R
    Dean, NM
    Levin, AA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 296 (02): : 388 - 395
  • [42] Oligonucleotide pharmacology and formulation: G3139 anti-BCL2 phosphorothioate in Stealth(R) liposomes and gel implants
    Woodle, MC
    Raynaud, FI
    Dizik, M
    Meyer, O
    Huang, SK
    Jaeger, JA
    Brown, BD
    Orr, R
    Judson, IR
    Papahadjopoulos, D
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1997, 16 (7-9): : 1731 - 1734
  • [43] Downregulation of BCL-2 expression by the antisense oligonucleotide G3139 enhances paclitaxel chemosensitivity in the androgen-independent prostate cancer LNCaP xenograft model.
    Tolcher, AW
    Miyake, H
    Gleave, M
    CLINICAL CANCER RESEARCH, 1999, 5 : 3847S - 3847S
  • [44] G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line
    Joyner, DE
    Albritton, KH
    Bastar, JRD
    Randall, RL
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2006, 24 (03) : 474 - 480
  • [45] Bcl-2 antisense oligonucleotide, Genasense™ (G3139), decreases Bcl-2 protein expression and induces in vitro cytotoxicity against MV4-11 leukemia cells.
    Saginario, C
    Adamson, P
    Felix, CA
    BLOOD, 2002, 100 (11) : 563A - 563A
  • [46] A phase I, pharmacokinetic and biologic correlative study of G3139 (Bcl-2 antisense oligonucleotide) and Docetaxel in patients with hormone-refractory prostate cancer (HRPC).
    Tolcher, AW
    Kuhn, J
    Basler, J
    Ochoa, L
    Schwartz, G
    Patnaik, A
    Hammond, L
    Smetzer, L
    Smith, L
    Fingert, H
    Weitman, S
    Thompson, I
    Rowinsky, EK
    CLINICAL CANCER RESEARCH, 2000, 6 : 4571S - 4571S
  • [47] Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes
    Chiu, Shih-Jiuan
    Liu, Shujun
    Perrotti, Danilo
    Marcucci, Guido
    Lee, Robert J.
    JOURNAL OF CONTROLLED RELEASE, 2006, 112 (02) : 199 - 207
  • [48] Phase I trial of g3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A Children's Oncology Group study
    Rheingold, Susan R.
    Hogarty, Michael D.
    Blaney, Susan M.
    Zwiebel, James A.
    Sauk-Schubert, Calies
    Chandula, Reddy
    Krailo, Mark D.
    Adamson, Peter C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1512 - 1518
  • [49] Transferrin Receptor Targeted Lipopolyplexes for Delivery of Antisense Oligonucleotide G3139 in a Murine K562 Xenograft Model
    Zhang, Xulang
    Koh, Chee Guan
    Yu, Bo
    Liu, Shujun
    Piao, Longzhu
    Marcucci, Guido
    Lee, Robert J.
    Lee, L. James
    PHARMACEUTICAL RESEARCH, 2009, 26 (06) : 1516 - 1524
  • [50] Phase I study of G3139, a Bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with previously untreated extensive stage small cell lung cancer
    Rudin, CM
    Kozloff, M
    Hoffman, PC
    Szeto, L
    Vokes, EE
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S147 - S148
12345